{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:21Z","timestamp":1792011261194,"version":"4.4.0"},"reference-count":257,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ctrv.2012.12.003","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T13:15:25Z","timestamp":1357218925000},"page":"647-663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies"],"prefix":"10.1016","volume":"39","author":[{"given":"Patrizia","family":"Limonta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Manea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.12.003_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"6","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2012.12.003_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0090-4295(02)01639-4","article-title":"Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?","volume":"60","author":"Labrie","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14656566.9.2.211","article-title":"Androgen deprivation therapy for prostate cancer","volume":"9","author":"Singer","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ctrv.2012.12.003_b0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1349-7006.2010.01774.x","article-title":"Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness","volume":"102","author":"Akaza","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2012.12.003_b0025","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.24395","article-title":"Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival","volume":"115","author":"Akaza","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1464-410x.2004.04803.x","article-title":"A re-assessment of the role of combined androgen blockade for advanced prostate cancer","volume":"93","author":"Klotz","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mce.2012.03.002","article-title":"Endocrine prevention and treatment of prostate cancer","volume":"360","author":"Tammela","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0040","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.clinthera.2006.10.018","article-title":"Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy","volume":"28","author":"Moreau","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ctrv.2012.12.003_b0045","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/j.urology.2011.05.051","article-title":"Traditional approaches to androgen deprivation therapy","volume":"78","author":"Moul","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/DHPS.S24106","article-title":"Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer","volume":"3","author":"Choi","year":"2011","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.ctrv.2012.12.003_b0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/j.1939-4640.2004.tb02791.x","article-title":"Medical castration with LHRH agonists: 25years later with major benefits achieved on survival in prostate cancer","volume":"25","author":"Labrie","year":"2004","journal-title":"J Androl"},{"key":"10.1016\/j.ctrv.2012.12.003_b0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/er.2004-0017","article-title":"Gonadotropin-releasing hormone agonists in the treatment of prostate cancer","volume":"26","author":"Labrie","year":"2005","journal-title":"Endocr Rev"},{"issue":"Suppl 6","key":"10.1016\/j.ctrv.2012.12.003_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1464-410X.2012.11215.x","article-title":"Androgen deprivation therapy: past, present and future","volume":"109","author":"Schroder","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CCO.0b013e3283380939","article-title":"Update on castrate-resistant prostate cancer: 2010","volume":"22","author":"Lassi","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0075","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.urolonc.2012.01.009","article-title":"Life after failure of traditional androgen deprivation therapy","volume":"30","author":"Schellhammer","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.06.007","article-title":"Progression of prostate cancer: multiple pathways to androgen independence","volume":"274","author":"Devlin","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2012.12.003_b0085","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.eururo.2009.06.027","article-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment targets","volume":"56","author":"Chi","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0090","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0095","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.12.003_b0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1464-410X.2008.08256.x","article-title":"The role of systemic cytotoxic therapy for prostate cancer","volume":"103","author":"Chang","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2009.11.019","article-title":"Molecular and traditional chemotherapy: a united front against prostate cancer","volume":"293","author":"Singh","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2012.12.003_b0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jcb.22022","article-title":"Mechanisms of prostate cancer cell survival after inhibition of AR expression","volume":"106","author":"Cohen","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0115","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-10-0567","article-title":"New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway","volume":"17","author":"Attard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0120","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.eururo.2011.12.028","article-title":"Novel molecular targets for the therapy of castration-resistant prostate cancer","volume":"61","author":"Agarwal","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2012.00085","article-title":"A changing landscape in castration-resistant prostate cancer treatment","volume":"3","author":"Felici","year":"2012","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0130","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.ejca.2011.04.036","article-title":"Management of metastatic castration-resistant prostate cancer after first-line docetaxel","volume":"47","author":"Harrington","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0135","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/1078-0432.CCR-10-2654","article-title":"Overcoming chemotherapy resistance in prostate cancer","volume":"17","author":"Madan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2009.08.012","article-title":"Novel targeted therapeutics for metastatic castration-resistant prostate cancer","volume":"291","author":"Antonarakis","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2012.12.003_b0145","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.juro.2010.10.042","article-title":"Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling","volume":"185","author":"Molina","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756287211432777","article-title":"Emerging novel therapies for advanced prostate cancer","volume":"4","author":"Osanto","year":"2012","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0155","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1464-410X.2011.10886.x","article-title":"Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities","volume":"110","author":"Payne","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0160","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1158\/1078-0432.CCR-10-1113","article-title":"Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists","volume":"16","author":"Liu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0006-291X(71)90766-2","article-title":"Isolation and properties of the FSH and LH-releasing hormone","volume":"43","author":"Schally","year":"1971","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ctrv.2012.12.003_b0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn","year":"1994","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ctrv.2012.12.003_b0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1210\/er.2003-0039","article-title":"Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans","volume":"26","author":"Cheng","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2012.12.003_b0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.anireprosci.2005.05.032","article-title":"GnRHs and GnRH receptors","volume":"88","author":"Millar","year":"2005","journal-title":"Anim Reprod Sci"},{"key":"10.1016\/j.ctrv.2012.12.003_b0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1677\/erc.1.00777","article-title":"Gonadotropin-releasing hormone and its receptor in normal and malignant cells","volume":"11","author":"Harrison","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0190","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1210\/er.2012-1014","article-title":"GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies","volume":"33","author":"Limonta","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2012.12.003_b0195","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/endo-128-6-3199","article-title":"Computer-assisted mapping of immunoreactive mammalian gonadotropin-releasing hormone in adult human basal forebrain and amygdala","volume":"128","author":"Stopa","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0200","first-page":"69","article-title":"The mammalian GnRH gene and its pivotal role in reproduction","volume":"43","author":"Seeburg","year":"1987","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0205","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1093\/nar\/17.15.6403","article-title":"The complete nucleotide sequence of the human gonadotropin-releasing hormone gene","volume":"17","author":"Hayflick","year":"1989","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/mend-4-3-476","article-title":"Isolation and characterization of the human gonadotropin-releasing hormone gene in the hypothalamus and placenta","volume":"4","author":"Radovick","year":"1990","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1210\/er.2003-0002","article-title":"Gonadotropin-releasing hormone receptors","volume":"25","author":"Millar","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2012.12.003_b0220","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/endo.143.3.8705","article-title":"GnRH and GnRH receptor genes in the human genome","volume":"143","author":"Neill","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0225","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1210\/edrv-15-4-462","article-title":"Gonadotropin-releasing hormone receptors: structure and signal transduction pathways","volume":"15","author":"Stojilkovic","year":"1994","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2012.12.003_b0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0083-6729(04)69006-6","article-title":"Gonadotropin-releasing hormone receptors: structure, expression, and signaling transduction","volume":"69","author":"Kakar","year":"2004","journal-title":"Vitam Horm"},{"key":"10.1016\/j.ctrv.2012.12.003_b0235","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0006-291X(92)91556-6","article-title":"Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor","volume":"189","author":"Kakar","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ctrv.2012.12.003_b0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.anireprosci.2005.05.004","article-title":"Pituitary gonadotropin-releasing hormone (GnRH) receptor: structure, distribution and regulation of expression","volume":"88","author":"Rispoli","year":"2005","journal-title":"Anim Reprod Sci"},{"key":"10.1016\/j.ctrv.2012.12.003_b0245","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0303-7207(94)90087-6","article-title":"The human gonadotropin-releasing hormone (GnRH) receptor gene: cloning, genomic organization and chromosomal assignment","volume":"103","author":"Fan","year":"1994","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0250","first-page":"46","article-title":"Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines","volume":"18","author":"Kaiser","year":"1997","journal-title":"Endocr Rev"},{"issue":"Pt 2","key":"10.1016\/j.ctrv.2012.12.003_b0255","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/bj3000299","article-title":"Absence of rapid desensitization of the mouse gonadotropin-releasing hormone receptor","volume":"300","author":"Davidson","year":"1994","journal-title":"Biochem J"},{"key":"10.1016\/j.ctrv.2012.12.003_b0260","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1210\/endo.141.12.7813","article-title":"Desensitization and internalization of human and xenopus gonadotropin-releasing hormone receptors expressed in alphaT4 pituitary cells using recombinant adenovirus","volume":"141","author":"Hislop","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.0.1730001","article-title":"Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors","volume":"173","author":"McArdle","year":"2002","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0270","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0188-4409(01)00331-9","article-title":"Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor","volume":"32","author":"Kraus","year":"2001","journal-title":"Arch Med Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0275","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0091-3022(03)00027-X","article-title":"Structure of the GnRH receptor-stimulated signaling network: insights from genomics","volume":"24","author":"Ruf","year":"2003","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yfrne.2008.07.001","article-title":"Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor","volume":"30","author":"Naor","year":"2009","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0285","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2174\/138955712800959080","article-title":"Gonadotropin-releasing hormone receptor signaling: biased and unbiased","volume":"12","author":"McArdle","year":"2012","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0290","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1210\/jc.2010-0245","article-title":"The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism","volume":"95","author":"Dwyer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0295","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2265.2009.03746.x","article-title":"What is the optimal therapy for young males with hypogonadotropic hypogonadism?","volume":"72","author":"Han","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ctrv.2012.12.003_b0300","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/oxfordjournals.humrep.a138714","article-title":"The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers","volume":"9","author":"Emons","year":"1994","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ctrv.2012.12.003_b0305","first-page":"CD006919","article-title":"Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction","author":"Maheshwari","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2012.12.003_b0310","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/2230-8210.85575","article-title":"Gonadotropin releasing hormone agonists: expanding vistas","volume":"15","author":"Magon","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0315","first-page":"15","article-title":"The treatment of polycystic ovary syndrome","volume":"56","author":"Ajossa","year":"2004","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0320","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.coph.2003.06.009","article-title":"Gonadotropin-releasing hormone antagonists","volume":"3","author":"Herbst","year":"2003","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2012.12.003_b0325","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.ejogrb.2004.01.033","article-title":"GnRH antagonists","volume":"115","author":"Coccia","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0330","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/humrep\/dem270","article-title":"Are GnRH antagonists comparable to agonists for use in IVF?","volume":"22","author":"Huirne","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ctrv.2012.12.003_b0335","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.yfrne.2003.10.003","article-title":"The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans","volume":"24","author":"Limonta","year":"2003","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/156800906776842966","article-title":"Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?","volume":"6","author":"Marelli","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ctrv.2012.12.003_b0345","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543784.10.4.709","article-title":"Montagnani Marelli M, Moretti RM, LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action","volume":"10","author":"Limonta","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2012.12.003_b0350","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/frne.2001.0217","article-title":"Hypothalamic hormones and cancer","volume":"22","author":"Schally","year":"2001","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0355","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study","volume":"92","author":"Klijn","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2012.12.003_b0360","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1452::AID-CNCR12>3.0.CO;2-Z","article-title":"Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group","volume":"78","author":"Emons","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0365","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ncpendmet0399","article-title":"Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone","volume":"3","author":"Engel","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0370","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1477-7827-1-65","article-title":"Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer","volume":"1","author":"Grundker","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1460001","article-title":"Biology of the gonadotropin-releasing hormone system in gynecological cancers","volume":"146","author":"Grundker","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0380","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/17425240903418410","article-title":"Receptor-mediated tumor targeting based on peptide hormones","volume":"7","author":"Mezo","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ctrv.2012.12.003_b0385","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.2174\/092986708785909157","article-title":"New derivatives of GnRH as potential anticancer therapeutic agents","volume":"15","author":"Mezo","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0390","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1210\/endo-106-3-707","article-title":"Comparative aspects of luteinizing hormone-releasing hormone structure and function in vertebrate phylogeny","volume":"106","author":"King","year":"1980","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0395","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-5793(98)01064-3","article-title":"A second isoform of gonadotropin-releasing hormone is present in the brain of human and rodents","volume":"435","author":"Chen","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ctrv.2012.12.003_b0400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1073\/pnas.95.1.305","article-title":"Second gene for gonadotropin-releasing hormone in humans","volume":"95","author":"White","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.12.003_b0405","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1210\/endo.142.1.7895","article-title":"Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells","volume":"142","author":"Kang","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0410","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0303-7207(03)00076-5","article-title":"Multi-factorial role of GnRH-I and GnRH-II in the human ovary","volume":"202","author":"Leung","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0415","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2826.2004.01229.x","article-title":"Emerging functions of gonadotropin-releasing hormone II in mammalian physiology and behaviour","volume":"16","author":"Kauffman","year":"2004","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0420","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/rep.0.1260271","article-title":"Type II gonadotrophin-releasing hormone (GnRH-II) in reproductive biology","volume":"126","author":"Pawson","year":"2003","journal-title":"Reproduction"},{"key":"10.1016\/j.ctrv.2012.12.003_b0425","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/molehr\/7.5.447","article-title":"Expression of the second isoform of gonadotrophin-releasing hormone (GnRH-II) in human endometrium throughout the menstrual cycle","volume":"7","author":"Cheon","year":"2001","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.ctrv.2012.12.003_b0430","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1006\/bbrc.2001.4678","article-title":"A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates","volume":"282","author":"Neill","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ctrv.2012.12.003_b0435","doi-asserted-by":"crossref","first-page":"9636","DOI":"10.1073\/pnas.141048498","article-title":"A novel mammalian receptor for the evolutionarily conserved type II GnRH","volume":"98","author":"Millar","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.12.003_b0440","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1043-2760(04)00186-9","article-title":"Newly recognized GnRH receptors: function and relative role","volume":"15","author":"Neill","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/geno.2001.6650","article-title":"The genes encoding the type II gonadotropin-releasing hormone receptor and the ribonucleoprotein RBM8A in humans overlap in two genomic loci","volume":"78","author":"Faurholm","year":"2001","journal-title":"Genomics"},{"key":"10.1016\/j.ctrv.2012.12.003_b0450","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1210\/jcem.87.3.8437","article-title":"Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation","volume":"87","author":"Grundker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0455","first-page":"893020","article-title":"Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells","author":"Kim","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0460","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1530\/eje.1.01996","article-title":"Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen","volume":"153","author":"Gunthert","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0465","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1210\/jc.2008-1741","article-title":"Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells","volume":"94","author":"Montagnani Marelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0470","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1477-7827-7-81","article-title":"Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase","volume":"7","author":"Park","year":"2009","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0475","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1210\/jc.2004-1636","article-title":"Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation","volume":"90","author":"Kim","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0480","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1677\/erc.1.01033","article-title":"Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway","volume":"13","author":"Kim","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0485","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/endo.132.3.8440174","article-title":"Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain","volume":"132","author":"Sower","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0490","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/gcen.1994.1134","article-title":"Effects of lamprey gonadotropin-releasing hormone-III on steroidogenesis and spermiation in male sea lampreys","volume":"95","author":"Deragon","year":"1994","journal-title":"Gen Comp Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0495","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1399-3011.1998.tb00662.x","article-title":"Direct anticancer activity of gonadotropin-releasing hormone-III","volume":"52","author":"Lovas","year":"1998","journal-title":"J Pept Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0500","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2826.2002.00828.x","article-title":"Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats","volume":"14","author":"Kovacs","year":"2002","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0505","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.peptides.2007.01.003","article-title":"Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs","volume":"28","author":"Kovacs","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.ctrv.2012.12.003_b0510","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1210\/edrv.18.2.0295","article-title":"Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor","volume":"18","author":"Sealfon","year":"1997","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2012.12.003_b0515","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1471-4159.1988.tb01084.x","article-title":"Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo","volume":"51","author":"Molineaux","year":"1988","journal-title":"J Neurochem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0520","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1210\/jcem-37-4-626","article-title":"The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in man","volume":"37","author":"Redding","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0525","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/j.1879-3479.1980.tb00507.x","article-title":"LH-RH agonists and antagonists","volume":"18","author":"Schally","year":"1980","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ctrv.2012.12.003_b0530","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/edrv-7-1-44","article-title":"Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective","volume":"7","author":"Karten","year":"1986","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2012.12.003_b0535","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anireprosci.2005.05.005","article-title":"GnRH analogues \u2013 agonists and antagonists","volume":"88","author":"Padula","year":"2005","journal-title":"Anim Reprod Sci"},{"key":"10.1016\/j.ctrv.2012.12.003_b0540","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1517\/13543770903410237","article-title":"Luteinizing hormone-releasing hormone antagonists","volume":"19","author":"Mezo","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.ctrv.2012.12.003_b0545","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/GCO.0b013e328348a3ce","article-title":"Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists","volume":"23","author":"Tan","year":"2011","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0550","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0140-6736(01)06797-6","article-title":"Gonadotropin-releasing-hormone-receptor antagonists","volume":"358","author":"Huirne","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.12.003_b0555","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/09513599909167587","article-title":"LH-RH analogues: I. Their impact on reproductive medicine","volume":"13","author":"Schally","year":"1999","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0560","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0010-7824(84)80008-6","article-title":"[Ac-d-NAL(2)1,4Fd-Phe2, d-Trp3, d-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats","volume":"29","author":"Schmidt","year":"1984","journal-title":"Contraception"},{"key":"10.1016\/j.ctrv.2012.12.003_b0565","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/13543784.2011.574611","article-title":"Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer","volume":"20","author":"Liu","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2012.12.003_b0570","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/pros.21169","article-title":"Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors","volume":"70","author":"Festuccia","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b0575","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/14737140.5.4.605","article-title":"Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?","volume":"5","author":"Cox","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2012.12.003_b0580","first-page":"259","article-title":"Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer","volume":"4","author":"Sethi","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.ctrv.2012.12.003_b0585","first-page":"19","article-title":"Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle","volume":"30","author":"Asch","year":"1985","journal-title":"Int J Fertil"},{"key":"10.1016\/j.ctrv.2012.12.003_b0590","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1073\/pnas.81.18.5845","article-title":"Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules","volume":"81","author":"Redding","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.12.003_b0595","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/CMAR.S12700","article-title":"Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort","volume":"3","author":"Crawford","year":"2011","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0600","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0022-5347(05)00161-8","article-title":"A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer","volume":"175","author":"Crawford","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0605","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/pcan.2011.50","article-title":"Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer","volume":"15","author":"Spitz","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2012.12.003_b0610","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2165\/11319690-000000000-00000","article-title":"Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study","volume":"29","author":"Lundstrom","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ctrv.2012.12.003_b0615","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1464-410X.2011.10370.x","article-title":"Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer","volume":"109","author":"Shore","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0620","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1517\/14656566.2010.529900","article-title":"Triptorelin embonate: a 6-month formulation for prostate cancer","volume":"11","author":"Whelan","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ctrv.2012.12.003_b0625","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0630","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/11588930-000000000-00000","article-title":"Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer","volume":"71","author":"Saylor","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2012.12.003_b0635","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/cncr.26623","article-title":"Androgen deprivation and thromboembolic events in men with prostate cancer","volume":"118","author":"Ehdaie","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0640","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0022-5347(05)67533-7","article-title":"Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0645","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0650","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0655","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.12.003_b0660","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2012.12.003_b0665","first-page":"2275","article-title":"Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma","volume":"50","author":"Bruchovsky","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0670","first-page":"121","article-title":"Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial","volume":"63","author":"Mottet","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0675","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tem.2008.09.003","article-title":"Will GnRH antagonists improve prostate cancer treatment?","volume":"20","author":"Huhtaniemi","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0680","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","article-title":"Gonadotropin-releasing hormone: an update review of the antagonists versus agonists","volume":"19","author":"Van Poppel","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0685","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756287211414457","article-title":"An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer","volume":"3","author":"Boccon-Gibod","year":"2011","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0690","first-page":"5063","article-title":"GnRH antagonists in the treatment of advanced prostate cancer","volume":"17","author":"Pommerville","year":"2010","journal-title":"Can J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0695","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/j.1464-410X.2009.08924.x","article-title":"Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer","volume":"104","author":"Kirby","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0700","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0196-9781(99)00130-8","article-title":"Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis","volume":"20","author":"Schally","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.ctrv.2012.12.003_b0705","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/humupd\/6.4.322","article-title":"The LHRH antagonist cetrorelix: a review","volume":"6","author":"Reissmann","year":"2000","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ctrv.2012.12.003_b0710","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.urology.2009.09.077","article-title":"Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia","volume":"76","author":"Debruyne","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0715","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0022-5347(05)66353-7","article-title":"The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer","volume":"165","author":"Tomera","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0720","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0090-4295(01)01342-5","article-title":"A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer","volume":"58","author":"McLeod","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0725","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0090-4295(03)00656-3","article-title":"An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists","volume":"62","author":"Koch","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0730","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/00005392-200204000-00021","article-title":"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer","volume":"167","author":"Trachtenberg","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0735","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0091270004264920","article-title":"Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75","volume":"44","author":"Wong","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0740","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1464-410X.2011.10708.x","article-title":"New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist","volume":"110","author":"Garnick","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0745","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1517\/14656566.5.10.2171","article-title":"Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer","volume":"5","author":"Mongiat-Artus","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ctrv.2012.12.003_b0750","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1016\/j.urology.2011.06.058","article-title":"New data, new paradigms for treating prostate cancer patients \u2013 VI: novel hormonal therapy approaches","volume":"78","author":"Dreicer","year":"2011","journal-title":"Urology"},{"issue":"Pt 2","key":"10.1016\/j.ctrv.2012.12.003_b0755","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.clinthera.2009.11.009","article-title":"Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer","volume":"31","author":"Steinberg","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.ctrv.2012.12.003_b0760","article-title":"New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists","author":"Shore","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2012.12.003_b0765","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.urology.2012.01.092","article-title":"The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients","volume":"80","author":"Damber","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0770","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.juro.2011.04.083","article-title":"A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer","volume":"186","author":"Crawford","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0775","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/jm0003900","article-title":"GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6","volume":"44","author":"Jiang","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0780","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1124\/jpet.106.112326","article-title":"Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist","volume":"320","author":"Princivalle","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2012.12.003_b0785","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.301.1.95","article-title":"Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix","volume":"301","author":"Broqua","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2012.12.003_b0790","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2125.2010.03730.x","article-title":"Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples","volume":"70","author":"Koechling","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0795","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.juro.2008.07.033","article-title":"A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America","volume":"180","author":"Gittelman","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0800","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.eururo.2008.04.065","article-title":"Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker \u2013 results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer","volume":"54","author":"Van Poppel","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0805","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0810","first-page":"1","article-title":"Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses","author":"Ulmert","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ctrv.2012.12.003_b0815","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","article-title":"Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide","volume":"110","author":"Axcrona","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2012.12.003_b0820","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix","volume":"186","author":"Smith","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0825","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/pcan.2011.11","article-title":"Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide","volume":"14","author":"Iversen","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2012.12.003_b0830","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1742-1241.2011.02637.x","article-title":"Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer","volume":"65","author":"de la Rosette","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ctrv.2012.12.003_b0835","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1016\/j.bmc.2008.05.024","article-title":"2-Phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor","volume":"16","author":"Pelletier","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0840","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/jm701249f","article-title":"Non-peptide gonadotropin-releasing hormone receptor antagonists","volume":"51","author":"Betz","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0845","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.102.046656","article-title":"Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats","volume":"305","author":"Anderes","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2012.12.003_b0850","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/cmdc.201100318","article-title":"Silicon analogues of the nonpeptidic GnRH antagonist AG-045572: syntheses, crystal structure analyses, and pharmacological characterization","volume":"6","author":"Barnes","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0855","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1067\/mob.2002.119633","article-title":"Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues","volume":"186","author":"Volker","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0860","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/gyno.1994.1264","article-title":"Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium","volume":"55","author":"Imai","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0865","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00662399","article-title":"Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters","volume":"25","author":"Baumann","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.12.003_b0870","first-page":"797","article-title":"Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP","volume":"76","author":"Limonta","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0875","first-page":"4091","article-title":"Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop","volume":"54","author":"Dondi","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0880","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1210\/endo-127-6-3052","article-title":"Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75","volume":"127","author":"Srkalovic","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0885","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1210\/endo.140.11.7087","article-title":"The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway","volume":"140","author":"Limonta","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0890","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0022-5347(05)67947-5","article-title":"High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers","volume":"163","author":"Halmos","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0895","first-page":"2340","article-title":"Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers","volume":"7","author":"Straub","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0900","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0090-4295(03)00042-6","article-title":"Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer","volume":"62","author":"Straub","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0905","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urolonc.2005.04.001","article-title":"Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma","volume":"23","author":"Szabo","year":"2005","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0910","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/path.1767","article-title":"Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer","volume":"206","author":"Gnanapragasam","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0915","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/pros.1072","article-title":"Gonadotropin-releasing hormone receptor expression in the human prostate","volume":"47","author":"Tieva","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b0920","first-page":"221","article-title":"Gonadotropin-releasing hormone receptors in prostate tissue","volume":"24","author":"Bono","year":"2002","journal-title":"Anal Quant Cytol Histol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0925","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1677\/erc.0.0100161","article-title":"Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression","volume":"10","author":"Moretti","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0930","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1210\/en.2010-0163","article-title":"Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis","volume":"151","author":"Moretti","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b0935","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1507\/endocrj.43.249","article-title":"Signal transduction of GnRH receptor in the reproductive tract tumor","volume":"43","author":"Imai","year":"1996","journal-title":"Endocr J"},{"key":"10.1016\/j.ctrv.2012.12.003_b0940","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<132::AID-CNCR22>3.0.CO;2-5","article-title":"Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane","volume":"77","author":"Imai","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0945","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1158\/0008-5472.CAN-04-1360","article-title":"Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor","volume":"64","author":"Maudsley","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0950","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/pros.21308","article-title":"Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells","volume":"71","author":"Morgan","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b0955","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2005.02.038","article-title":"Gonadotropin-releasing hormone in apoptosis of prostate cancer cells","volume":"234","author":"Kraus","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2012.12.003_b0960","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1158\/0008-5472.CAN-04-1156","article-title":"Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways","volume":"64","author":"Kraus","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0965","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/sj.onc.1204265","article-title":"Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front","volume":"20","author":"Paweletz","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2012.12.003_b0970","first-page":"1168","article-title":"Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer","volume":"8","author":"Malik","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b0975","doi-asserted-by":"crossref","first-page":"24500","DOI":"10.1074\/jbc.M003145200","article-title":"Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression","volume":"275","author":"Graff","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b0980","first-page":"261","article-title":"Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I","volume":"30","author":"Montagnani Marelli","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b0985","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/sj.bjc.6602350","article-title":"Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline","volume":"92","author":"Yates","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b0990","first-page":"3930","article-title":"Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145","volume":"81","author":"Moretti","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b0995","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1210\/endo.140.1.6402","article-title":"Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells","volume":"140","author":"Marelli","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b1000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0083-6729(00)59002-5","article-title":"GnRH receptor and apoptotic signaling","volume":"59","author":"Imai","year":"2000","journal-title":"Vitam Horm"},{"key":"10.1016\/j.ctrv.2012.12.003_b1005","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1111\/j.1742-4658.2008.06677.x","article-title":"Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues","volume":"275","author":"Cheung","year":"2008","journal-title":"FEBS J"},{"key":"10.1016\/j.ctrv.2012.12.003_b1010","first-page":"207","article-title":"Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP","volume":"75","author":"Limonta","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b1015","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/(SICI)1097-0215(19980518)76:4<506::AID-IJC11>3.0.CO;2-5","article-title":"Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice","volume":"76","author":"Dondi","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b1020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1677\/joe.0.1760275","article-title":"Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus","volume":"176","author":"Franklin","year":"2003","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1025","first-page":"1251","article-title":"Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling","volume":"8","author":"Wells","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b1030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/pros.20954","article-title":"Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas","volume":"69","author":"Clementi","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b1035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/07357900600629591","article-title":"Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma","volume":"24","author":"Castellon","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2012.12.003_b1040","first-page":"393","article-title":"GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system","volume":"15","author":"Dondi","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2012.12.003_b1045","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1210\/en.2005-0460","article-title":"Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells","volume":"147","author":"Enomoto","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b1050","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.juro.2010.10.055","article-title":"Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence","volume":"185","author":"Lawrentschuk","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yfrne.2007.06.002","article-title":"Diversity of actions of GnRHs mediated by ligand-induced selective signaling","volume":"29","author":"Millar","year":"2008","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1060","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/en.2004-0461","article-title":"Outside-in and inside-out signaling: the new concept that selectivity of ligand binding at the gonadotropin-releasing hormone receptor is modulated by the intracellular environment","volume":"145","author":"Millar","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b1065","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0959-8049(97)00072-5","article-title":"Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II","volume":"33","author":"Jungwirth","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b1070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1097-0045(19970801)32:3<164::AID-PROS2>3.0.CO;2-L","article-title":"Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice","volume":"32","author":"Jungwirth","year":"1997","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b1075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-0115(98)00119-0","article-title":"Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors","volume":"77","author":"Lamharzi","year":"1998","journal-title":"Regul Pept"},{"key":"10.1016\/j.ctrv.2012.12.003_b1080","article-title":"A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA","author":"Masson-Lecomte","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1530\/eje.0.1510141","article-title":"Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor","volume":"151","author":"Grundker","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1677\/ERC-07-0041","article-title":"Expression of GnRH type II is regulated by the androgen receptor in prostate cancer","volume":"14","author":"Darby","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2012.12.003_b1095","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1210\/jc.2004-1894","article-title":"Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death","volume":"90","author":"Maiti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.12.003_b1100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/0008-5472.CAN-08-2115","article-title":"A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b1105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2108\/zsj.21.1005","article-title":"GnRH as a cell proliferation regulator: mechanism of action and evolutionary implications","volume":"21","author":"Enomoto","year":"2004","journal-title":"Zoolog Sci"},{"key":"10.1016\/j.ctrv.2012.12.003_b1110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1410001","article-title":"Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors","volume":"141","author":"Schally","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1115","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1073\/pnas.89.3.972","article-title":"Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups","volume":"89","author":"Janaky","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.12.003_b1120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/pros.2990230209","article-title":"Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals","volume":"23","author":"Pinski","year":"1993","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b1125","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1073\/pnas.93.14.7269","article-title":"Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500\u20131000 times more potent","volume":"93","author":"Nagy","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.12.003_b1130","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1073\/pnas.86.16.6313","article-title":"Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone","volume":"86","author":"Bajusz","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.12.003_b1135","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1095\/biolreprod.105.043489","article-title":"Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers","volume":"73","author":"Nagy","year":"2005","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ctrv.2012.12.003_b1140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/156720111793663598","article-title":"Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors","volume":"8","author":"Schally","year":"2011","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.ctrv.2012.12.003_b1145","first-page":"877","article-title":"Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin","volume":"10","author":"Jungwirth","year":"1997","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1097-0045(19990201)38:2<151::AID-PROS9>3.0.CO;2-#","article-title":"Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice","volume":"38","author":"Koppan","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b1155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3835(01)00734-0","article-title":"Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207","volume":"176","author":"Plonowski","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2012.12.003_b1160","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pros.20335","article-title":"Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207","volume":"66","author":"Stangelberger","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b1165","first-page":"4505","article-title":"Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers","volume":"9","author":"Letsch","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b1170","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1517\/13543784.2012.685128","article-title":"AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors","volume":"21","author":"Engel","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2012.12.003_b1175","first-page":"1063","article-title":"Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines","volume":"17","author":"Westphalen","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1180","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.ajog.2004.04.020","article-title":"Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system","volume":"191","author":"Gunthert","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-004-8806-8","article-title":"Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system","volume":"87","author":"Gunthert","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.12.003_b1190","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.97.2.829","article-title":"Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies","volume":"97","author":"Nagy","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.12.003_b1195","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1530\/eje.0.1430569","article-title":"Cytotoxic luteinizing hormone-releasing hormone conjugates and their use in gynecological cancer therapy","volume":"143","author":"Grundker","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1200","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1535-7163.MCT-08-0988","article-title":"Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy","volume":"8","author":"Sundaram","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2012.12.003_b1205","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1021\/jm9700981","article-title":"Synthesis of gonadotropin-releasing hormone III analogs. Structure\u2013antitumor activity relationships","volume":"40","author":"Mezo","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b1210","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/bc800542u","article-title":"Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug","volume":"20","author":"Szabo","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b1215","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00726-010-0766-1","article-title":"In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites","volume":"41","author":"Orban","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.ctrv.2012.12.003_b1220","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jconrel.2011.08.005","article-title":"Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect","volume":"156","author":"Schlage","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.ctrv.2012.12.003_b1225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CAD.0b013e32834bb6b4","article-title":"In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice","volume":"23","author":"Manea","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2012.12.003_b1230","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1021\/bc100547p","article-title":"Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4","volume":"22","author":"Manea","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b1235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2012.08.014","article-title":"Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates","volume":"56","author":"Hegedus","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b1240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejmech.2012.03.016","article-title":"GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate","volume":"52","author":"Leurs","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ctrv.2012.12.003_b1245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bip.21640","article-title":"Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety","volume":"98","author":"Leurs","year":"2012","journal-title":"Biopolymers"},{"key":"10.1016\/j.ctrv.2012.12.003_b1250","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0005-2736(99)00210-2","article-title":"Effects of the hinge region of cecropin A(1\u20138)-magainin 2(1\u201312), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells","volume":"1463","author":"Shin","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctrv.2012.12.003_b1255","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2174\/1381612043383971","article-title":"Membrane disrupting lytic peptides for cancer treatments","volume":"10","author":"Leuschner","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ctrv.2012.12.003_b1260","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pros.10259","article-title":"Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors","volume":"56","author":"Leuschner","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2012.12.003_b1265","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2006.06.017","article-title":"Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases","volume":"269","author":"Hansel","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bcp.2010.09.015","article-title":"LHRH-conjugated lytic peptides directly target prostate cancer cells","volume":"81","author":"Yates","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2012.12.003_b1275","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00240-003-0352-z","article-title":"GnRH-PAP hormonotoxin targets cytotoxicity to prostate cancer cell lines","volume":"31","author":"Qi","year":"2003","journal-title":"Urol Res"},{"key":"10.1016\/j.ctrv.2012.12.003_b1280","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1210\/en.2002-220917","article-title":"Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors","volume":"144","author":"Yang","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.12.003_b1285","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/0008-5472.CAN-3192-2","article-title":"Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor","volume":"64","author":"Qi","year":"2004","journal-title":"Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212002423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212002423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T03:12:43Z","timestamp":1714792363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212002423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":257,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0305737212002423"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}